Cantor Fitzgerald Analysts Give Teva Pharmaceutical Industries (TEVA) a $18.00 Price Target

Teva Pharmaceutical Industries (NYSE:TEVA) received a $18.00 price target from analysts at Cantor Fitzgerald in a note issued to investors on Thursday. The brokerage presently has a “hold” rating on the stock. Cantor Fitzgerald’s price target points to a potential downside of 5.26% from the stock’s previous close.

TEVA has been the topic of a number of other reports. ValuEngine lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Morgan Stanley set a $15.00 price target on Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a research note on Thursday, October 5th. Mizuho reaffirmed a “hold” rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries in a research note on Monday, October 30th. Finally, Piper Jaffray Companies set a $23.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, October 6th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $20.99.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded down $0.10 on Thursday, reaching $19.00. The company’s stock had a trading volume of 11,386,900 shares, compared to its average volume of 16,626,293. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $38.31. The firm has a market capitalization of $19,405.60, a price-to-earnings ratio of -3.19 and a beta of 0.55.

A number of large investors have recently bought and sold shares of TEVA. Capital Research Global Investors raised its holdings in shares of Teva Pharmaceutical Industries by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the period. Franklin Resources Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the period. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the period. Macquarie Group Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after buying an additional 3,429,448 shares during the period. Finally, Capital World Investors raised its holdings in shares of Teva Pharmaceutical Industries by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares during the period. Institutional investors own 51.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Teva Pharmaceutical Industries (TEVA) a $18.00 Price Target” was first posted by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/29/cantor-fitzgerald-analysts-give-teva-pharmaceutical-industries-teva-a-18-00-price-target.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.